Targeting CD20 in melanoma patients at high risk of disease recurrence.
about
Nanoparticle-mediated drug delivery for treating melanomaB cells and the humoral response in melanoma: The overlooked players of the tumor microenvironmentNovel applications of Rituximab in dermatological disordersSOX2 regulates self-renewal and tumorigenicity of human melanoma-initiating cells.Melanocytes, melanocyte stem cells, and melanoma stem cells.Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations.Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.Melanoma stem cells.Cancer stem cells: a potential target for cancer therapy.The role of cancer stem cells in tumor heterogeneity and resistance to therapy.Isolation of melanoma cell subpopulations using negative selection.Tumor-associated B-cells induce tumor heterogeneity and therapy resistance.Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches.Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.Salinomycin-loaded lipid-polymer nanoparticles with anti-CD20 aptamers selectively suppress human CD20+ melanoma stem cells.All-trans retinoic acid-encapsulated, CD20 antibody-conjugated poly(lactic--glycolic acid) nanoparticles effectively target and eliminate melanoma-initiating cells in vitro
P2860
Q26798379-08C43239-8B4D-432A-B0D0-F12919B08615Q33632113-409C960B-ED81-4AF8-84F3-CC1F43D83C5BQ34087599-303FCC04-58F1-413F-8810-40AE880801BDQ34269756-18C5B8F4-132C-4916-9CCA-7AF1A6DFDE7CQ36640682-6BB01189-07A6-443F-A7F5-41CC5AC0BC8FQ37615286-F4311ACA-917D-4C60-B823-7A230578C414Q38041729-DDBC4E33-76D0-4ED3-85B5-5F24DA605C22Q38218786-D34FCCD4-5503-44EF-AF05-176F1C5FE632Q38335943-966881FE-4741-47EF-868C-D26E8CF3F99FQ38476034-C9AF15AF-F3C6-454F-85D4-9BA4590EDFC8Q39031410-B57F71FD-7ED0-4BCC-9405-DB24954DCDE5Q39060277-38CDAE8D-9B3B-4391-9965-4798A63A274AQ41701119-BECED0A1-0F06-4C93-B90A-1593A4262593Q42000150-539A15D3-6A18-4FEE-98FA-06C136A504B7Q47227422-8806BA10-BED6-41F9-9C73-6B837D702097Q49501113-D76615B8-40FB-4B29-AF35-74118F21791DQ57069994-55DF417A-09D0-4B26-9921-19A483FC6059
P2860
Targeting CD20 in melanoma patients at high risk of disease recurrence.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting CD20 in melanoma patients at high risk of disease recurrence.
@ast
Targeting CD20 in melanoma patients at high risk of disease recurrence.
@en
type
label
Targeting CD20 in melanoma patients at high risk of disease recurrence.
@ast
Targeting CD20 in melanoma patients at high risk of disease recurrence.
@en
prefLabel
Targeting CD20 in melanoma patients at high risk of disease recurrence.
@ast
Targeting CD20 in melanoma patients at high risk of disease recurrence.
@en
P2093
P2860
P50
P356
P1433
P1476
Targeting CD20 in melanoma patients at high risk of disease recurrence
@en
P2093
Ahmad Jalili
Alice Pinc
Chiou-Yan Lai
Christine Wagner
Georg Stingl
Georgios Karanikas
Katharina Grabmeier-Pfistershammer
Marcus Hörmann
Meenhard Herlyn
Mei-Yu Hsu
P2860
P304
P356
10.1038/MT.2012.27
P577
2012-02-21T00:00:00Z